Answers are grounded in this paper and cite their sources.
Pancreatic adenocarcinoma has a poor 5-year survival rate despite many advancements in pharmacotherapies. Studies have suggested the involvement of β-adrenergic pathway in the progression of pancreatic adenocarcinoma. Animal experiments and retrospective trials have reported the use of beta-blockers as potential chemo-preventative agents. This review aims to discuss β-adrenergic physiology as it relates to the progression of pancreatic adenocarcinoma and review outcomes on the use of beta-blockers for its treatment.
No takes yet. Share an insight, caveat, or question.
Upadhyaya et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: